Biocure Technology Inc.
Biocure Technology Inc.
CSE Index:
Currency:
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE)
SEDAR Information
Company Info
Address
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaPhone
604-609-7146Fax
N/AEmail
admin@biocuretech.comWebsite
http://www.biocuretech.comListing date
Monday, May 10, 2010Transfer Agent
Computershare Investor Services Inc.Investor Relations
Purple Crown Communications Corp.Email
Julie@purplecrown.caAuditor
DMCL Chartered Professional AccountantsCapitalization
Issued & Outstanding:
94000537Reserved for Issuance:
14510547Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
Bulletins
18/09/2023
2023-0927 - Halted for Fundamental Change - Biocure Technology Inc. (CURE)
le 18 septembre/September 2023
Trading in the shares of Biocure Technology Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Acquisition pursuant to CSE Policy 8. This regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange, pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.
